ID

24552

Description

Study part: Study Conclusion. A 52-Week, Open-Label Study to Assess the Long-Term Safety of Ropinirole Extended Release (XR) in Patients with Restless Legs Syndrome (RLS). Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Clinicaltrials.gov Identifier: NCT00355641. Phase: phase 3. Study Recruitment Status: Completed. Generic Name: ropinirole. Trade Name Modutab, ZIPEREVE, ZEPREVE, REPREVE, ADARTREL, REQUIP, Zygara; Zygara, ZIPEREVE, ZEPREVE, Requip Depot, REQUIP, REPREVE, Modutab, ADARTREL. Study Indication : Restless Legs Syndrome. Study ID: 101468/206. Clinical Study ID: 101468/206.

Keywords

Versions (1)
  1. 8/5/17 8/5/17 -
Copyright Holder

GlaxoSmithKline

Uploaded on

August 5, 2017

DOI

To request one please log in.

License

Creative Commons BY-NC 3.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Study Conclusion (CONC) Ropinirole Restless Legs Syndrom NCT00355641

English

Study Conclusion

1 forms  
  1. StudyEvent: ODM
    1. Study Conclusion
STUDY CONCLUSION
Description

STUDY CONCLUSION

Alias
UMLS CUI-1
C1707478
UMLS CUI-2
C0008972
1. Date of subject completion or date of subject withdrawal
Description

date subject withdrawal

Data type

date

Alias
UMLS CUI [1,1]
C0011008
UMLS CUI [1,2]
C0422727
2. Was the subject withdrawn from the study?
Description

subject withdrawal

Data type

boolean

Alias
UMLS CUI [1]
C0422727
If Yes, select primary reason for withdrawal
Description

reason

Data type

text

Alias
UMLS CUI [1]
C0392360
Other, specify
Description

Other

Data type

text

Alias
UMLS CUI [1]
C0205394
LOG STATUS
Description

LOG STATUS

Alias
UMLS CUI-1
C1708728
UMLS CUI-2
C0449438
3. Did the subject experience any non-serious adverse events during the study?
Description

non-serious adverse events

Data type

boolean

Alias
UMLS CUI [1]
C1518404
4. Did the subject experience any serious adverse events during the study?
Description

serious adverse events

Data type

boolean

Alias
UMLS CUI [1]
C1519255
5. Were any concomitant medications taken by the subject prior to screening and/or during the study?
Description

concomitant medications

Data type

boolean

Alias
UMLS CUI [1]
C2347852
6. Case book ready for signature
Description

signature

Data type

boolean

Alias
UMLS CUI [1]
C1519316
7. Q1
Description

Q1

Data type

boolean

8. Q2
Description

Q2

Data type

text

Back to the top of the page

Similar models

Study Conclusion

1 forms
  1. StudyEvent: ODM
    1. Study Conclusion
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
STUDY CONCLUSION
C1707478 (UMLS CUI-1)
C0008972 (UMLS CUI-2)
date subject withdrawal
Item
1. Date of subject completion or date of subject withdrawal
date
C0011008 (UMLS CUI [1,1])
C0422727 (UMLS CUI [1,2])
subject withdrawal
Item
2. Was the subject withdrawn from the study?
boolean
C0422727 (UMLS CUI [1])
Item
If Yes, select primary reason for withdrawal
text
C0392360 (UMLS CUI [1])
reason
Code List
If Yes, select primary reason for withdrawal
CL Item
Adverse Event (Adverse Event)
C0877248 (UMLS CUI-1)
(Comment:en)
CL Item
Lost to follow-up (Lost to follow-up)
C1302313 (UMLS CUI-1)
(Comment:en)
CL Item
Protocol violation (Protocol violation)
C1709750 (UMLS CUI-1)
(Comment:en)
CL Item
Subject decided to withdraw from the study (Subject decided to withdraw from the study)
C2348571 (UMLS CUI-1)
(Comment:en)
CL Item
Insufficient therapeutic effect (Insufficient therapeutic effect)
C1546939 (UMLS CUI-1)
(Comment:en)
CL Item
Other (Other)
C0205394 (UMLS CUI-1)
(Comment:en)
Other
Item
Other, specify
text
C0205394 (UMLS CUI [1])
Item Group
LOG STATUS
C1708728 (UMLS CUI-1)
C0449438 (UMLS CUI-2)
non-serious adverse events
Item
3. Did the subject experience any non-serious adverse events during the study?
boolean
C1518404 (UMLS CUI [1])
serious adverse events
Item
4. Did the subject experience any serious adverse events during the study?
boolean
C1519255 (UMLS CUI [1])
concomitant medications
Item
5. Were any concomitant medications taken by the subject prior to screening and/or during the study?
boolean
C2347852 (UMLS CUI [1])
signature
Item
6. Case book ready for signature
boolean
C1519316 (UMLS CUI [1])
Q1
Item
7. Q1
boolean
Item
8. Q2
text
Q2
Code List
8. Q2
CL Item
PF_SC_LOST (PF_SC_LOST)
CL Item
PF_SC_DEATH (PF_SC_DEATH)
CL Item
PF_SC_SPONSORDECISION (PF_SC_SPONSORDECISION)
CL Item
PF_SC_PHYSICIANDECISION (PF_SC_PHYSICIANDECISION)
CL Item
PF_SC_PATIENTDECISION (PF_SC_PATIENTDECISION)
CL Item
PF_SC_AE (PF_SC_AE)
CL Item
PF_SC_ALE (PF_SC_ALE)
CL Item
PF_SC_CRITERIA (PF_SC_CRITERIA)
CL Item
PF_SC_OTHER (PF_SC_OTHER)
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial